ArticleJournal of nanobiotechnology2019
Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori.
Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Characterization ofFrontiers in microbiology · 2026Article
- Nanoemulsion as a promising drug delivery strategy for effective eradication of Helicobacter pylori: current insights.Drug delivery and translational research · 2026Review
- Review
- Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes.Pharmaceutics · 2025Review
- Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.Frontiers in immunology · 2025Review
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- An Updated Review on Nanoemulsion: Factory for Food and Drug Delivery.Current pharmaceutical biotechnology · 2024Review
- Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections.World journal of microbiology & biotechnology · 2023Article
- Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.Acta pharmaceutica Sinica. B · 2022Review
- Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks.Colloid and interface science communications · 2021Review
- Review
- O/W Nanoemulsion as an Adjuvant for an Inactivated H3N2 Influenza Vaccine: Based on Particle Properties and Mode of Carrying.International journal of nanomedicine · 2020Article
- Biomaterials forGut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHelicobacter pylori (H. pylori) infection remains a global public health issue, especially in Asia. Due to the emergence of antibiotic-resistant strains and the complexity of H. pylori infection, conventional vaccination is the best way to control the disease. Our previous study found that the N-acetyl-neuroaminyllactose-binding hemagglutinin protein (HpaA) is an effective protective antigen for vaccination against H. pylori infection, and intranasal immunization with the immunodominant HpaA epitope peptide (HpaA 154-171, P22, MEGVLIPAGFIKVTILEP) in conjunction with a CpG adjuvant decreased bacterial colonization in H. pylori-infected mice. However, to confer more robust and effective protection against H. pylori infection, an optimized delivery system is needed to enhance the P22-specific memory T cell response.
resultsIn this study, an intranasal nanoemulsion (NE) delivery system offering high vaccine efficacy without obvious cytotoxicity was designed and produced. We found that this highly stable system significantly prolonged the nasal residence time and enhanced the cellular uptake of the epitope peptide, which powerfully boosted the specific Th1 responses of the NE-P22 vaccine, thus reducing bacterial colonization without CpG. Furthermore, the protection efficacy was further enhanced by combining the NE-P22 vaccine with CpG.
conclusionThis epitope-loaded nanoemulsion delivery system was shown to extend antigen release and elicit potent Th1 response, it is an applicable delivery system for intranasal vaccine against H. pylori.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.